The drugmaker said it is the only U.S. company with FDA-approved medications containing semaglutide, the active ingredient for Ozempic, Wegovy and Rybelsus, and unapproved compounded solutions with semaglutide jeopardize public health, according to court documents. Novo Nordisk also accused the compounding pharmacies of unfair competition and hurting the drug company’s reputation.
The three Florida pharmacies are Live Well Drugstore in Green Cove Springs, WellHealth in Jacksonville and Brooksville Pharmaceuticals in Brooksville. Novo Nordisk requests at least $75,000 from each location.
This is the second time Novo Nordisk has sued over Ozempic copycats. In June, it filed suit against six spas and clinics for similar allegations.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
